Table 1.

Characteristics of patients on dialysis and control subjects who received the Pfizer BNT162b2 vaccine

FactorDialysis Group, n=56Control Group, n=95
Age, yr74 (11)57 (9)
Sex, women, n (%)14 (25)69 (73)
BMI, kg/m2 27.2 (4)
Diabetes mellitus, n (%)35 (63)6 (6)
Immunosuppression medication, n (%)1 (2)4 (4)
Kidney failure etiology, diabetes or nephrosclerosis, n (%)41 (72)
Transplantation candidate (%)13 (23)
Dialysis vintage, mo38 (37)
Dialysis access, AVF, n (%)42 (74)
Mean Kt/V1.33 (0.23)
Days after first dose, median (IQR)a 53 (42–56)52 (41–60)
Days after second dose, median (IQR)b 30 (27–34)30 (26–34)
White blood cell count, 10 e3/µl7.9 (3.1)
Polymorphonuclears count, 10 e3/µl5.5 (2.4)
Lymphocyte count, 10 e3/µl1.5 (0.6)
Serum albumin, g/dL4.0 (0.35)
  • Values are mean (SD), unless otherwise stated. BMI, body mass index; AVF, arteriovenous fistula; IQR, interquartile range.

  • a Range is 34–60 days for the study group and 35–67 days for the control group.

  • b Range is 12–34 days for the study group and 14–34 days for the control group.